Committed to Overcoming the Challenges of Targeted Delivery of Cancer Therapies
TransCode Therapeutics is dedicated to bringing the power of targeted delivery of therapeutics to oncology.
By applying our TTX delivery platform, TransCode is able to boldly do what no other company has done before:
TTX also opens the door for us to harness RNA’s ability to target a vast number of genes and cellular pathways with high specificity. The rapid and cost-effective development of these therapies also allows for the easy modification to address personalized medicine and evolving targets.
TransCode is committed to revolutionizing the future of cancer treatment through application of the TTX platform to deliver cancer therapeutics to their intended targets. We won’t stop in our mission to leverage TTX to find new targets and treatments.
Delivering Where it Matters Most
TransCode Therapeutics is initially focusing on the area of oncology with the largest unmet need -- metastatic disease -- cancers that spread from the organ of origin to other parts of the body. Given the absence of treatments targeting metastatic disease, TransCode is applying their TTX platform in the metastatic setting to transform the lives of people with metastatic disease and improve outcomes.
We are immediately focused on the urgent need for metastatic breast cancer treatment and are extending our TTX platform and therapy there. Additional focus is in rare forms of metastatic disease such as pancreatic cancer, glioblastoma, small cell lung cancer, osteosarcoma and neurofibromatosis - all indications that include microRNA-10b as the driver.
Rooted in our fundamental principle to change how all cancer is treated and in our commitment to patients, TransCode aims to extend TTX across multiple tumor indications and across all stages of cancer.
Steeg PS. Targeting metastasis. Nat Rev Cancer. 2016;16(4):201-218. Liang X, et al. Biomed Pharmacother. 2020;125:109997.;
Damase TR, et al. Frontiers in Bioengineering and Biotechnology. 2021;9.; Dowdy SF. Nat Biotechnol. 2017;35(3):222-229.